This study aimed to evaluate the association of IDH1 (R132H) IHC as a surrogate marker within the World Health Organization (WHO) integrated framework and to correlate the expression of IDH1 (R132H) with clinicopathological parameters in gliomas. This evidence concerns the gene IDH1 and central nervous system cancer.